KV Acquires Particle and Coating Technologies
This article was originally published in The Pink Sheet Daily
PCT’s Proprietary coating technologies will augment KV’s development of both generics and branded products, firm says.
You may also be interested in...
KV believes it has 180-day exclusivity for the 100 mg and 200 mg strengths of the hypertension treatment.
Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee